Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning

New England Journal of Medicine, 2017

Moffitt Cancer Center, University of Kentucky, Markey Cancer Center, Cedars-Sinai Medical Center, The University of Texas MD Anderson Cancer Center, Stanford University, Dana-Farber Cancer Institute, University of Iowa, Zentralklinik Bad Berka, The Royal Free Hospital, University College London, Hôpital Beaujon, Mayo Clinic, Excel Diagnostics Imaging, KU Leuven, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Indo-American Center, King's College Hospital NHS Foundation Trust, Charité - Universitätsmedizin Berlin, Bellvitge University Hospital, Vanderbilt University Medical Center, Hospital Universitario Ramón y Cajal, Beatson West of Scotland Cancer Centre, Fondazione IRCCS Istituto Nazionale dei Tumori, Advanced Applications (United States), Erasmus MC

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

3080

Citations

View on Google Scholar

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Abstract

Journal Details

Join JournalsHub

Welcome Back